Europe Life Sciences Weekly Signal #50: Who Controls the Route to Market?
WEEK OF 10–16 AUGUST 2026 · 15-MINUTE READ This week, the decisive choices sat outside the product team. Switzerland offered the clearest warning. An industry survey found that companies had withheld seven of 22 new medicines from reimbursement submission because a Swiss price could affect their economics in the United States. In three further cases,…